Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,811 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer.
Danno K, Hata T, Tamai K, Fujie Y, Ide Y, Kim HM, Ohnishi T, Morita S, Yoshioka S, Kudo T, Nishimura J, Matsuda C, Akamatsu H, Mizushima T, Nezu R, Doki Y, Mori M; Multi-Center Clinical Study Group of Osaka; Colorectal Cancer Treatment Group (MCSGO). Danno K, et al. Among authors: kudo t. Cancer Chemother Pharmacol. 2017 Oct;80(4):777-785. doi: 10.1007/s00280-017-3419-1. Epub 2017 Aug 19. Cancer Chemother Pharmacol. 2017. PMID: 28825216 Clinical Trial.
Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
Kotaka M, Iwamoto S, Satake H, Sakai D, Kudo T, Fukunaga M, Konishi K, Ide Y, Ikumoto T, Tsuji A, Sano Y, Kato T, Sugimoto N, Satoh T, Kanazawa A, Kurata T, Yamanaka T, Tomita N. Kotaka M, et al. Among authors: kudo t. Int J Clin Oncol. 2020 Aug;25(8):1515-1522. doi: 10.1007/s10147-020-01701-1. Epub 2020 May 14. Int J Clin Oncol. 2020. PMID: 32409917 Clinical Trial.
Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study.
Yoshikawa AK, Yamaguchi K, Muro K, Takashima A, Ichimura T, Sakai D, Kadowaki S, Chin K, Kudo T, Mitani S, Kitano S, Thai D, Zavodovskaya M, Liu J, Boku N, Satoh T. Yoshikawa AK, et al. Among authors: kudo t. J Immunother Cancer. 2022 Jan;10(1):e003518. doi: 10.1136/jitc-2021-003518. J Immunother Cancer. 2022. PMID: 34992093 Free PMC article. Clinical Trial.
A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer.
Eguchi H, Nagano H, Kobayashi S, Kawamoto K, Wada H, Hama N, Tomimaru Y, Akita H, Sakai D, Satoh T, Kudo T, Isohashi F, Mori M, Doki Y. Eguchi H, et al. Among authors: kudo t. Cancer Chemother Pharmacol. 2014 Feb;73(2):309-15. doi: 10.1007/s00280-013-2357-9. Epub 2013 Nov 21. Cancer Chemother Pharmacol. 2014. PMID: 24258457 Clinical Trial.
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, Tateishi R, Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX. Kudo M, et al. Among authors: kudo t. J Gastroenterol. 2017 Apr;52(4):494-503. doi: 10.1007/s00535-016-1247-4. Epub 2016 Aug 22. J Gastroenterol. 2017. PMID: 27549242 Clinical Trial.
Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.
Mizushima T, Fukunaga M, Sueda T, Ikeda M, Kato T, Kim HM, Kudo T, Murata K, Nishimura J, Hata T, Matsuda C, Yamamoto H, Doki Y, Mori M. Mizushima T, et al. Among authors: kudo t. Cancer Chemother Pharmacol. 2017 Jul;80(1):81-90. doi: 10.1007/s00280-017-3336-3. Epub 2017 May 16. Cancer Chemother Pharmacol. 2017. PMID: 28510802 Clinical Trial.
Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
Kudo M, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Nadano S, Ohkawa K, Fujii H, Kudo T, Furuse J, Takai H, Homma G, Yoshikawa R, Zhu AX. Kudo M, et al. Among authors: kudo t. J Gastroenterol. 2020 Jun;55(6):627-639. doi: 10.1007/s00535-020-01668-w. Epub 2020 Feb 27. J Gastroenterol. 2020. PMID: 32107609 Free PMC article. Clinical Trial.
2,811 results